SEARCH:   Advanced

Blood, 1 April 2006, Vol. 107, No. 7, pp. 2766-2773. Prepublished online as a Blood First Edition Paper on January 5, 2006; DOI 10.1182/blood-2005-09-3578. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-09-3578v1 107/7/2766    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dentali, F. Articles by Ageno, W. Search for Related Content PubMed PubMed Citation Articles by Dentali, F. Articles by Ageno, W. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis Francesco Dentali, Mark Crowther, and Walter Ageno From the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; and the Department of Clinical Medicine, University of Insubria, Varese, Italy. Recent studies suggest that thrombophilic abnormalities and the use of oral contraceptives (OCs) are the leading causes of cerebral vein thrombosis (CVT). The purpose of this study was to assess the association between CVT and thrombophilic states, OCs, and their interaction. For data sources, we used the MEDLINE, EMBASE, and Cochrane Library databases (January 1994 to March 2005), reference lists of retrieved articles, and contact with content experts. We selected studies comparing the prevalence of OC use and the prevalence of prothrombitic abnormalities in patients with CVT compared with healthy controls. Two reviewers independently selected studies and extracted study characteristics, quality, and outcomes. Odds ratios (ORs) were calculated for each trial and pooled using the Mantel-Haenszel method. Seventeen studies were included. There was an increased risk of CVT in patients using OCs (OR 5.59; 95% confidence interval [CI] 3.95 to 7.91; P < .001), and in patients with factor V Leiden (OR 3.38; 95% CI 2.27 to 5.05; P < .001), with mutation G20 210A of prothrombin (OR 9.27; 95% CI 5.85 to 14.67; P < .001) and with hyperhomocysteinemia (OR 4.07; 95% CI 2.54 to 6.52; P < .001). We concluded that OC users, and patients with factor V Leiden, the prothrombin G20 120A mutation, and hyperhomocysteinemia are at a significantly increased risk of CVT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. M. Coutinho, J. M. Ferro, P. Canhao, F. Barinagarrementeria, C. Cantu, M.-G. Bousser, and J. Stam Cerebral Venous and Sinus Thrombosis in Women Stroke, July 1, 2009; 40(7): 2356 - 2361. [Abstract] [Full Text] [PDF] I. Martinelli, M. Franchini, and P. M. Mannucci How I treat rare venous thromboses Blood, December 15, 2008; 112(13): 4818 - 4823. [Abstract] [Full Text] [PDF] F. Dentali, M. Gianni, M. A. Crowther, and W. Ageno Natural history of cerebral vein thrombosis: a systematic review Blood, August 15, 2006; 108(4): 1129 - 1134. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020